



Generate Collection

L20: Entry 41 of 56

File: USPT

Jun 16, 1998

DOCUMENT-IDENTIFIER: US 5767103 A

TITLE: Nitric oxide sequestrant

Brief Summary Text (8):

Nitric oxide is synthesized in mammalian cells from the amino acid L-arginine by a family of enzymes, the nitric oxide synthases, via the L-arginine-nitric oxide pathway. Moncada et al. (1993) N. Engl. J. Med., 329:2002-2012. The production of nitric oxide via the nitric oxide-arginine pathway begins when a guanidine nitrogen of L-arginine undergoes a five-electron oxidation to yield the gaseous radical nitric oxide via an N.sup.w -hydroxyl-L-arginine intermediate. NADPH (nicotine adenine diphosphonucleotide, reduced) donates two electrons for the formation of this intermediate and one electron for its further oxidation. Both steps are catalyzed by nitric oxide synthase. In addition to the gaseous radical nitric oxide, L-citrulline is also produced. Molecular oxygen is incorporated into both the L-citrulline and the nitric oxide formed. Tetrahydrobiopterin is required for the oxidation of the intermediate, N.sup.w -hydroxyl-L-arginine, to L-citrulline. The amount of tetrahydrobiopterin required is substoichiometric with respect to the nitric oxide generated, provided that tetrahydrobiopterin can be regenerated from its oxidized form, quinonoid dihydrobiopterin.

Brief Summary Text (10):

Under basal conditions, endothelium-derived nitric oxide is produced by cNOS, a calcium- and calmodulin-dependant nitric oxide synthase. Constitutive nitric oxide synthase is controlled by cell surface receptors and can be activated by a variety of vasodilators including acetylcholine, bradykinin, histamine and adenosine. This enzyme is always present in the vascular endothelium of mammals. The interaction of acetylcholine or bradykinin with their receptors on vascular endothelium results in production of intracellular calcium which stimulates cNOS. The nitric oxide formed from L-arginine diffuses to nearby smooth muscle cells where it stimulates the soluble guanylate cyclase, resulting in enhanced synthesis of cyclic guanosine monophosphate (cGMP). The cGMP formed causes smooth muscle cells to relax. The formation of cGMP regulates physiological vascular tone, blood pressure and tissue perfusion by mediating endothelium-dependent relaxation and neural transmission.

Brief Summary Text (12):

The synthesis of nitric oxide from L-arginine occurs in numerous cells and tissues. Examples of cells which produce nitric oxide include: neutrophils, megakaryocytes, Kupffer cells, macrophages, endothelial cells, hepatocytes, murine fibroblasts and EMT-6 cells. Examples of tissues that generate nitric oxide include: vascular smooth muscle, the brain, the adrenal gland, endocardium, peripheral and sensory nerves and the myocardium. Moncada et al. (1993) N. Engl. J. Med., 329: 2002-2012.

Other Reference Publication (1):

J.A. Lorente, et al. "L-arginine Pathway in the Sepsis Syndrome"; Crit. Care Med.; 21: 1287-1295 (1993).

WEST

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Cases

Search Results -

Terms	Documents
L9 and (magnesium or lecithin or stearic or palmitic)	0

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Search History
DATE: Thursday, November 20, 2003 [Printable Copy](#) [Create Case](#)
Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L10</u>	L9 and (magnesium or lecithin or stearic or palmitic)	0	<u>L10</u>
<u>L9</u>	L7 and ethanol	1	<u>L9</u>
<u>L8</u>	L7 and ethaol	0	<u>L8</u>
<u>L7</u>	L6 and (surfactant)	1	<u>L7</u>
<u>L6</u>	6333023.pn.	1	<u>L6</u>
<u>L5</u>	L4 and (surfactant adj ethanol)	28	<u>L5</u>
<u>L4</u>	((424/\$)!.CCLS.)	65787	<u>L4</u>
<u>L3</u>	L2 and (ethanol adj\$4 surfactant)	1890	<u>L3</u>
<u>L2</u>	L1 and ((424/\$)!.CCLS.)	1890	<u>L2</u>
<u>L1</u>	(ethanol same surfactant)	11860	<u>L1</u>

END OF SEARCH HISTORY

☐ Generate Collection

L1: Entry 1 of 467

File: USPT

Nov 18, 2003

DOCUMENT-IDENTIFIER: US 6649418 B1

TITLE: Internally referenced competitive assays

Detailed Description Text (48):

As a matter of convenience, the present device can be provided in a kit in packaged combination with predetermined amounts of reagents for use in assaying for an analyte. Where an enzyme is used as the label, the substrate for the enzyme or precursors therefor including any additional substrates, enzymes and cofactors and any reaction partner of the enzymic product required to provide the detectable signal can be included. In addition, other additives such as ancillary reagents can be included, for example, stabilizers, buffers, and the like. The relative amounts of the various reagents can be varied widely, to provide for concentrations in solution of the reagents which substantially optimize the sensitivity of the assay. The reagents can be provided as dry powders, usually lyophilized, including excipients, which on dissolution will provide for a reagent solution having the appropriate concentrations for performing the assay. The kit can also be contained in packaging material, such as air-tight foil, or various external containers known in the art. Such external containers can contain the device, reagents, and the instructions for use of the device.



Generate Collection

L7: Entry 4 of 19

File: USPT

Apr 8, 2003

DOCUMENT-IDENTIFIER: US 6544994 B2

TITLE: Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase

Brief Summary Text (3):

The term tetrahydrobiopterin (BH.sub.4) or a derivative thereof, if not explicitly defined otherwise, always refers to all natural and unnatural stereoisomeric forms of tetrahydrobiopterin, pharmaceutically compatible salts thereof and any mixtures of the isomers and the salts. The term tetrahydrobiopterin also includes any precursors of tetrahydrobiopterin, especially 7,8-dihydrobiopterin. (6R)-tetrahydrobiopterin is a naturally occurring cofactor of the aromatic amino acid hydroxylases and is involved in the synthesis of the three common aromatic amino acids tyrosine, phenylalanine, tryptophan and the neurotransmitters dopamine and serotonin. It is also essential for nitric oxide synthase catalysed oxidation of L-arginine to L-citrullin and nitric oxide. Tetrahydrobiopterin is involved in many other biochemical functions, many of which have been just recently discovered.

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L1 same term	19

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Thursday, November 20, 2003 [Printable Copy](#) [Create Case](#)**Set Name Query**
side by side**Hit Count Set Name**
result set*DB=USPT; PLUR=YES; OP=OR*

<u>L7</u>	L1 same term	19	<u>L7</u>
<u>L6</u>	L1 same term same means	0	<u>L6</u>
<u>L5</u>	s	1626800	<u>L5</u>
<u>L4</u>	cofactor same increase same arginine	11	<u>L4</u>
<u>L3</u>	L1 and arginine	199	<u>L3</u>
<u>L2</u>	L1 and (tetrahydrobiopterin)	5	<u>L2</u>
<u>L1</u>	cofactor same precursor	467	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L7 and substrate	1

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** **Thursday, November 20, 2003** [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L14</u>	L7 and substrate	1	<u>L14</u>
<u>L13</u>	L7 and (nitric adj oxide adj synthase adj cofactor)	0	<u>L13</u>
<u>L12</u>	L7 and (nadph)	0	<u>L12</u>
<u>L11</u>	L7 and (tetrahydrobiopterin)	0	<u>L11</u>
<u>L10</u>	L7 and (extended)	0	<u>L10</u>
<u>L9</u>	L7 and (tablet or capsule or delayed or sustained)	0	<u>L9</u>
<u>L8</u>	L7 and (tablet or capsules or delayed or sustained)	0	<u>L8</u>
<u>L7</u>	L6 and (agent)	1	<u>L7</u>
<u>L6</u>	L5 and (alone or combination)	1	<u>L6</u>
<u>L5</u>	L4 and (cardiomyopathy or angina or atrial or fibrillation or tachycardia or infarction or cardiomegaly)	1	<u>L5</u>
<u>L4</u>	L3 and pulmonary	1	<u>L4</u>
<u>L3</u>	L2 and simvastatin	1	<u>L3</u>
<u>L2</u>	L1 and (cardio? or heart or coronary or hypertension)	2	<u>L2</u>
<i>DB=DWPI,USPT,EPAB,JPAB,TDBD; PLUR=YES; OP=OR</i>			
<u>L1</u>	6465516.pn.	2	<u>L1</u>

Hit Count Set Name

result set

END OF SEARCH HISTORY

WEST

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Cases

Search Results -

Terms	Documents
L19 and (arginine same nadph)	56

Database:

US Patents Full-Text Database

US Pre-Grant Publication Full-Text Database

JPO Abstracts Database

EPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Search History

DATE: Thursday, November 20, 2003 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,JPAB,EPAB,DWPI,TDBD; PLUR=YES; OP=OR

<u>L20</u>	L19 and (arginine same nadph)	56	<u>L20</u>
<u>L19</u>	L18 and (arginine same tetrahydrobiopterin)	58	<u>L19</u>
<u>L18</u>	L17 and l-arginine	61	<u>L18</u>
<u>L17</u>	L16 and tetrahydrobiopterin	68	<u>L17</u>
<u>L16</u>	L15 same (nitric adj oxide adj synthase)	112	<u>L16</u>
<u>L15</u>	nadph	3945	<u>L15</u>
<u>L14</u>	L7 and substrate	1	<u>L14</u>
<u>L13</u>	L7 and (nitric adj oxide adj synthase adj cofactor)	0	<u>L13</u>
<u>L12</u>	L7 and (nadph)	0	<u>L12</u>
<u>L11</u>	L7 and (tetrahydrobiopterin)	0	<u>L11</u>
<u>L10</u>	L7 and (extended)	0	<u>L10</u>
<u>L9</u>	L7 and (tablet or capsule or delayed or sustained)	0	<u>L9</u>
<u>L8</u>	L7 and (tablet or capsules or delayed or sustained)	0	<u>L8</u>
<u>L7</u>	L6 and (agent)	1	<u>L7</u>
<u>L6</u>	L5 and (alone or combination)	1	<u>L6</u>
<u>L5</u>	L4 and (cardiomyopathy or angina or atrial or fibrillation or tachycardia or infarction or cardiomegaly)	1	<u>L5</u>
<u>L4</u>	L3 and pulmonary	1	<u>L4</u>
<u>L3</u>	L2 and simvastatin	1	<u>L3</u>
<u>L2</u>	L1 and (cardo? or heart or coronary or hypertension)	2	<u>L2</u>
<i>DB=DWPI,USPT,EPAB,JPAB,TDBD; PLUR=YES; OP=OR</i>			
<u>L1</u>	6465516.pn.	2	<u>L1</u>

END OF SEARCH HISTORY

End of Result Set

Generate Collection

L14: Entry 1 of 1

File: USPT

Oct 15, 2002

US-PAT-NO: 6465516

DOCUMENT-IDENTIFIER: US 6465516 B1

TITLE: Method of stimulating nitric oxide synthase

DATE-ISSUED: October 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kaesemeyer; Wayne H.	Augusta	GA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Nitrosystems, Inc.	Augusta	GA			02

APPL-NO: 09/ 420328 [PALM]

DATE FILED: October 18, 1999

PARENT-CASE:

This Appln is a con't of Ser. No. 08/833,842 filed Apr. 10, 1997, U.S. Pat. No. 5,968,983.

INT-CL: [07] A61 K 31/22, A61 K 31/351, A61 K 31/405

US-CL-ISSUED: 514/548; 514/419, 514/460

US-CL-CURRENT: 514/548; 514/419, 514/460

FIELD-OF-SEARCH: 514/569, 514/565, 514/419, 514/460, 514/548

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>4444784</u>	April 1984	Hoffman et al.	424/279
<input type="checkbox"/>	<u>4686211</u>	August 1987	Hara et al.	514/148
<input type="checkbox"/>	<u>5059712</u>	October 1991	Griffith	562/560
<input type="checkbox"/>	<u>5132453</u>	July 1992	Griffith	562/560
<input type="checkbox"/>	<u>5158883</u>	October 1992	Griffith	435/240.2
<input type="checkbox"/>	<u>5196195</u>	March 1993	Griffith	424/94.6
<input type="checkbox"/>	<u>5270323</u>	December 1993	Milne, Jr. et al.	514/309
<input type="checkbox"/>	<u>5316765</u>	May 1994	Folkers et al.	424/94.1
<input type="checkbox"/>	<u>5428070</u>	June 1995	Cooke et al.	514/557
<input type="checkbox"/>	<u>5543430</u>	August 1996	Kaesemeyer	514/565
<input type="checkbox"/>	<u>5595970</u>	January 1997	Garfield et al.	514/12
<input type="checkbox"/>	<u>6147109</u>	January 2000	Liao et al.	514/460

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
0 671 171	September 1995	EP	
WO 98/34626	August 1998	WO	
WO 98/44893	October 1998	WO	
99/18952	April 1999	WO	
WO 99/47153	September 1999	WO	
WO 00/03746	January 2000	WO	
WO 00/40086	July 2000	WO	
WO 00/45809	August 2000	WO	
WO 00/56403	September 2000	WO	
WO 00/62614	October 2000	WO	

OTHER PUBLICATIONS

Otsuka et al., J. Hypertension (12, Suppl. 3. S108, 1994).*

Rubba et al., Current Opinion in Lipidology, 6:348-353 (1995).*

Egashira et al., Ann. N.Y. Acad. Sci., 748, 622-5, 1995 (abstract).*

Sunderkotter et al. Macrophages and angiogenesis. J. Leukoc. Biol. Mar. 1994, vol. 55, No. 3, pp. 410-420.

Bassenge, E. Coronary Vasomotor Responses: Role of Endothelium and Nitrovasodilators. Cardiovascular Drugs and Therapy. 1994, vol. 8, pp. 601-610.

O'Driscoll et al.: "the HMG-CoA reductase inhibitor simvastatin endothelial function within one month" Circulation, vol. 94, No. 8, 1996, pp. 1-401, XP002091894 (abstract).

Endres et al.: "stroke protection by HMG-CoA reductase inhibitors mediated by endothelial nitric oxide synthase" Proc Natl Acad Sci USA, vol. 95, No. 15, Jun. 21, 1998, pp. 8880-8885.

Endres et al.: "simvastatin pretreatment protects from focal cerebral ischemia" Stroke, vol. 29, No. 1, Jan. 1998, p. 325.

Di Napoli et al.: "simvastatin exerts a direct anti-ischemic effect" Eur>Heart J., vol. 19, Aug. 1998, p. 124.

Laufs et al.: "inhibition of HMG-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase" J Biol Chem, vol. 272, No. 50, Dec. 12, 1997, pp. 31725-31729.

Laufs et al.: "Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase." Journal of Biological Chemistry, (Sep. 11, 1998) 273 (37) 24266-71.

Ohara et al.: "Regulation of endothelial constitutive nitric oxide synthase by protein

- C" Hypertension, vol. 25, No. 3, Mar. 1995 pp. 515-420.
- Stroes et al.: "Cyclosporin A increases nitric oxide activity in vivo" Hypertension, vol. 29, No. 2, Feb. 1997, pp. 570-575.
- Lopez-Ongil et al.: "Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells" American Journal of Physiology, vol. 271, No. 3, Sep. 1996, p. H1072-8.
- Patel, J. M. et al. Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells. (Abstract Only) Free Radical Radical Biology & Medicine. vol. 20, No. 5. pp. 629. 1996.
- Xia, Y. et al. Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury. Proc. Natl. Acad. Sci. USA. vol. 93. pp. 6770-6774. Jun. 1996.
- Jeremy, R. W. et al. Effects of Dietary L-Arginine on Atheroscleriosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit. Circulation. vol. 94, No. 3. pp. 498-506, Aug. 1, 1996.
- Block, E. R. et al. Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells. (Abstract Only) Am. J. Physiol. vol. 269, L574-L580. 1995.
- Mayer, B. et al. Brain Nitric Oxide Synthase is a Biopterin-and Flavin-Containing Multi-Functional Oxido-Reductase. (Abstract Only) FEBS 10045. vol. 288, No. 1,2. pp. 187-191. Aug. 1991.
- Weidinger, F. F. et al. Persistent Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery. Circulation. vol. 81, No. 5. pp. 1667-1679. May 1990.
- Chester, A. H. et al. Low Basal and Stimulated Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries. The Lancet. vol. 336, pp. 897-900. Oct. 13, 1990.
- Albina, J. E. et al. Arginine Metabolism in Wounds. Am. J. Physiol. vol. 254. pp. E459-E467. 1988.
- Cooke, J.P. et al. Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit. (Abstract Only) J. Clin. Invest. vol. 90, No. 3. pp. 1168-1172. Sep. 1992.
- Nakamura, Y. et al. Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIGA Pravastatin Study). (Abstract Only). Cardiovasc. Drugs. Ther., vol. 10, No. 4, pp. 475-483. 1996.
- Pohl, U. et al. Effects of LDL on Intracellular Free Calcium and Nitric Oxide-Dependent cGMP Formation on Porcine Endothelial Cells. (Abstract only) Atherosclerosis. vol. 117. pp. 169-178. 1995.
- Deliconstantinos, G. et al. Modulation of Particulate Nitric Oxide Synthase Activity and Peroxynitrate Synthesis in Cholesterol Enriched Endothelial Cell Membranes. (Abstract Only) Biochem. Pharm. vol. 49, No. 11. pp. 1589-1600. 1995.
- Galle, J. et al. Effect of HDL and Atherogenic Lipoproteins on Formation of O₂ and Renin Release in Juxtaglomerular Cells. (Abstract Only) Kidney International. vol. 51, pp. 253-260. 1997.
- Bult, H. Nitric Oxide and Atherosclerosis: Possible Implications for Therapy. (Abstract only) Molecular Medicine Today. p. 510. Dec. 1996.
- Crouse III, J.R. et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). (Abstract only) Am. J. Cardiol. vol. 75. pp. 455-459. 1995.
- Aji, W. et al. L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice. (Abstract only) Circulation. vol. 95. pp. 430-437. 1997.
- Cooke, J. P. et al. Arginine: A new Therapy for Atherosclerosis?. Circulation. vol. 95. pp. 311-312. 1997.
- Boger, R. H. et al. The L-Arginine Nitric Oxide Pathway: Role in Atherosclerosis and Therapeutic Implications. (First page only) Atherosclerosis. vol. 127. pp. 1-11. 1996.
- Jay, M.T. et al. Modulation of Vascular Tone By Low Density Lipoproteins. Effects on L-Arginine Transport and Nitric Oxide Synthesis. Experimental Physiology. vol. 82. pp. 349-360. 1997.
- Muramatsu, J. et al. Hemodynamic Changes Associated with Reduction in Total Cholesterol By Treatment with the HMG-CoA Reductase Inhibitor Pravastatin. Atherosclerosis. vol. 130. pp. 179-182. 1997.
- Sacks, F. M. et al. The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels. The New England Journal of Medicine. vol. 335, pp. 1001-1009. Oct. 3, 1996.
- Bovan, A. J. van. et al. Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris,

Circulation. vol. 94. pp. 1503-1505. 1996.

Lacoste, L. et al. Comparative Effect of Pravastatin and Simvastatin on Platelet-Thrombus Formation in Hypercholesterolemic Coronary Patients. JACC. vol. 27 No. 2 Supp A. p. 413A. 1996.

Pitt, B. et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events. J. Am. Coll. Cardiol. vol. 26. pp. 1133-1139. 1995.

Candipan, R.C. et al. Regression or Progression: Dependency on Vascular Nitric Oxide. Arterioscler. Thromb. Vas. Biol. vol. 16. pp. 45-50. 1996.

Byington, R.P. et al. Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program. Circulation. vol. 92. pp. 2419-2425. 1995.

Pritchard, K.A. et al. Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion. Circ. Res. vol. 77 No. 3. pp. 510-518. 1995.

Boger, R.H. et al. Supplementation of Hypercholesterolemic Rabbits with L-Arginine Reduces the Vascular Release of Superoxide Anions and Restores NO Production. Artherosclerosis. vol. 117 No. 2. pp. 273-284. 1995.

Lacoste, L. et al. Correction of the Increased Thrombogenic Potential with Cholesterol Reduction. Circulation. vol. 92. pp. 3172-3177. 1995.

Shepard, J. Prevention of Coronary Heart Disease with Provastatin in Men with Hypercholesterolemia. The New England Journal of Medicine vol. 333. pp. 1301-1307. Nov. 16, 1995.

Philis-Tsimikas, A. et al. L-Arginine May Inhibit Atherosclerosis Through Inhibition of LDL Oxidation. Circulation. vol. 92 (Supp. I). pp. 1-422. 1995.

Von der Leyen, H.E. et al. Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene. Proc. Natl. Acad. Sci. USA. vol. 92. pp. 1137-1141. 1995.

Egashira, K. et al. Reduction in Serum Cholesterol with Pravastatin Improves Endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia. Circulation. vol. 89. pp. 2519-2524. 1994.

Tsao, P. et al. Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine. Circulation. vol. 89. pp. 2176-2182. 1994.

Cayatte, A.J. et al. Chronic Inhibition of Nitric Oxide Production Accelerates Neointima Formation and Impairs Endothelial Function in Hypercholesterolemic Rabbits. Arterioscler. Thomb. vol. 14. pp. 753-759. 1994.

Wilcox, J.N. et al. Expression of Multiple Nitric Oxide Synthase Isoforms in Human Aortic Fatty Streaks and Advanced Atherosclerotic Plaques. (Abstract only) Circulation. vol. 90 (Supp. I). pp. I-298. 1994.

Chen, L. Y. et al. Oxidated LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function. Circulation. vol. 93. pp. 1740-1746. 1993.

Wada, H. et al. Hypercoagulable State in Patients with Hypercholesterolemia: Effects of Pravastatin. Clin. Therap. vol. 14. pp. 829-834. 1992.

Drexler, H. et al. Correction of Endotelial Dysfunction in Coronary Microcirculation of Hypercholesterolaemia Patients by L-Arginine. The Lancet. vol. 338. pp. 1546-1550. Dec. 21/28, 1991.

Haman, M. et al. Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury. Circulation, vol. 90. No. 3, pp. 1357-1362. Sep., 1994.

Harrison, D.G. Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis. J. Am. Coll. Cardiol. vol. 17. pp. 71B-6B. 1991.

Cooke, J.P. et al. Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta. Circulation. vol. 83. pp. 1057-1062. 1991.

Witzum, J.L. et al. Role of Oxidized Low Density Lipoprotein in Atherogenesis. J. Clin. Invest. vol. 88. pp. 1785-1792. 1991.

Mugge, A.J. et al. Chronic Treament with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits. Circ. Res. vol. 69. pp. 1293-1300. 1991.

Forstermann, U. et al. Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries. Circ. Res. vol. 62. pp. 185-191. 1988.

Cohen, R.A. et al. Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia. Circ. Res. vol. 63. pp. 903-910. 1988.

Schwarzacher, A.P. et al. Locak Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty. Circulation,

vol. 95. No. 7. pp. 1863-1869. Apr. 1, 1997.

Verbeuren, T.J. et al. Effect of Hypercholesterolemia on Vascular Reactivity in the Rabbit., I: Endothelium-Dependent and Independent Contractions and Relaxations in Isolated Arteries of Control and Hypercholesterolemic Rabbits. Circ. Res. vol. 58. pp. 552-564. 1986.

Duggan, D.E. et al. The Physiological Disposition of Lovastatin. Drug Metabolism and Disposition, vol.17, No. 2. pp. 166-173. 1989.

Vickers, S. et al. Metabolic Disposition Studies on Simvastatin, a Cholesterol-Lowering Prodrug. Drug Metabolism and Disposition, vol. 18, No. 2. pp. 138-145. 1990.

ART-UNIT: 1614

PRIMARY-EXAMINER: Spivack; Phyllis G.

ATTY-AGENT-FIRM: Benesch, Friedlander, Coplan & Aronoff, LLP

ABSTRACT:

A method for treating a subject who would benefit from increased nitric oxide production comprising administering inhibitors of Hmg-CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction.

14 Claims, 2 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 2

BRIEF SUMMARY:

1 BACKGROUND OF THE INVENTION

2 This invention relates generally to a method of treating cardio-cerebrorenovascular disease as well as avoiding potential cardiocerebrorenovascular disease, and the symptoms thereof, wherein a substrate of Nitric Oxide Synthase ("NOS") and an agonist of NOS are combined to produce a beneficial effect.

3 DESCRIPTION OF RELATED ART

4 Much focus in the area of cardiac disease has been on the presence of cholesterol in the body. Hypercholesterolemia is known to be a primary risk factor for death from coronary heart disease. It is known that 50% or more of the total body cholesterol in humans is derived from intrinsic biosynthesis. It is also known that a rate-limiting step of major significance in the biosynthesis of cholesterol is at the level of the enzyme known as 3-hydroxy-3-methylglutaryl-coenzyme A reductase or Hmg-CoA reductase. A general class of compounds is known in the art which inhibit and reduce the intrinsic biosynthesis of cholesterol in order to reduce the risk factor of hypercholesterolemia and coronary artery death. This general class of compounds is known as inhibitors of Hmg-CoA reductase.

5 An alternative approach to treating cardiac disease is to effect the dilation of vascular conduits in the body. In this regard, nitric oxide has been shown to be formed enzymatically as a normal metabolite from arginine in vascular endothelium and provides an important component to the formation of endothelium-derived relaxing factor (EDRF). EDRF appears to be equivalent to Endothelium Derived Nitric Oxide (EDNO) and as used herein EDRF and EDNO are interchangeable unless otherwise indicated. Macrophages and neurons have also been shown to produce nitric oxide in the body as a component of their cell killing and/or cytosolic function.

6 Recently it has been established that a family of enzymes called Nitric Oxide Synthase ("NOS") form nitric oxide from L-arginine, and the nitric oxide produced is responsible for the endothelium dependent relaxation and activation of soluble

guanylate cyclase, neurotransmission in the central and peripheral nervous systems, and activated macrophage cytotoxicity.

- 7 Nitric Oxide Synthase, occurs in many distinct isoforms which include a constitutive form (cNOS) and an inducible form (iNOS). The constitutive form is present in normal endothelial cells, neurons and some other tissues. Formation of nitric oxide by the constitutive form in endothelial cells is thought to play an important role in normal blood pressure regulation, prevention of endothelial dysfunction such as hyperlipodemia, arteriosclerosis, thrombosis, and restenosis. The inducible form of nitric oxide synthase has been found to be present in activated macrophages and is induced in vascular smooth muscle cells, for example, by various cytokines and/or microbial products.
- 8 The conversion of precursor substrates of EDNO such as L-arginine into nitric oxide is enzymatically catalyzed by NOS and the resulting by-product of the conversion of L-arginine is L-citrulline. Although it was initially described in endothelium, NOS activity has now been described in many cell types. Brain, endothelium, and macrophage isoforms appear to be products of a variety of genes that have approximately 50% amino acid identity. NOS in brain and in endothelium have very similar properties, the major differences being that brain NOS is cytosolic and the endothelial enzyme is mainly a membrane-associated protein.
- 9 Functionally, the constitutive form of Nitric Oxide Synthase ("cNOS"), which is the predominant synthase present in brain and endothelium, may be active under basal conditions and can be further stimulated by increases in intracellular calcium that occur in response to receptor-mediated agonists or calcium ionophores. cNOS appears to be the "physiological" form of the enzyme and plays a role in a diverse group of biologic processes. In vitro studies suggest that the activity of nitric oxide synthase can be regulated in a negative feedback manner by nitric oxide itself. In cardiocerebrorenovascular circulation, the primary target for constitutively produced nitric oxide is believed to be soluble guanylate cyclase located in vascular smooth muscle, the myocardium (myocytes) and coronary vascular smooth muscle.
- 10 In contrast to the cNOS, the inducible, calcium-independent form, iNOS was initially only described in macrophages. It is now known that induction of nitric oxide synthase can occur in response to appropriate stimuli in many other cell types. This includes both cells that normally do not express a constitutive form of nitric oxide synthase, such as vascular smooth muscle cells, as well as cells such as those of the myocardium that express considerable levels of the constitutive isoform.
- 11 iNOS exhibits negligible activity under basal conditions, but in response to factors such as lipopolysaccharide and certain cytokines, expression occurs over a period of hours. The induced form of the enzyme produces much greater amounts of NO than the constitutive form, and induced NOS appears to be the "pathophysiological" form of the enzyme because high concentrations of NO produced by iNOS can be toxic to cells. Induction of iNOS can be inhibited by glucocorticoids and some cytokines. Relatively little is known about postranscriptional regulation of iNOS. Cytotoxic effects of NO are probably largely independent of guanylate cyclase and cyclic GMP formation. Most of the research in the area has focused on inhibitors of iNOS stimulation using various derivatives of L-arginine.
- 12 Research into the area of cNOS activation reveals a number of agonist of cNOS some of which have been described in U.S. Pat. No. 5,543,430, which is hereby incorporated by reference in its entirety. However, until now there was no known research indicating Hmg-CoA reductase inhibitors were capable of functioning as agonist of cNOS.
- 13 SUMMARY OF THE INVENTION
- 14 The term "subject" as used herein to mean any mammal, including humans, where nitric oxide formation from arginine occurs. The methods herein for use on subjects contemplate prophylactic use as well as curative use in therapy of an

existing condition.

- 15 The term "native NO" as used herein refers to nitric oxide that is produced through the bio-transformation of L-arginine or the L-arginine dependent pathway. "EDRF" or "EDNO" may be used interchangeably with "native NO". The term endpoints as used herein refers to clinical events encountered in the course of treating cardiovascular disease, up to and including death (mortality).
- 16 L-arginine as used herein includes all biochemical equivalents (i.e. salts, precursors, and its basic form). L-arginine as defined herein appears to function as a substrate of cNOS.
- 17 "To mix", "mixing", or "mixture(s)" as used herein means mixing a substrate (i.e. L-arginine) and an agonist (i.e. Hmg-CoA reductase inhibitor): 1) prior to administration ("in vitro mixing"); 2) mixing by simultaneous and/or consecutive, but separate (i.e. separate intravenous lines) administration of substrate (L-arginine and agonist to cause "in vivo mixing"; and 3) the administration of a NOS agonist after saturation with a NOS substrate (i.e. L-arginine is administered to build up a supply in the body prior to administering the NOS agonist (nitroglycerin or Hmg-CoA reductase)); or any combination of the above which results in the combination of therapeutic amounts of a NOS agonist and a (NOS substrate in an additive or synergistic way with regard to the treatment of vascular disease.
- 18 Agonist refers to an agent which stimulates the bio-transformation of a substrate such as L-arginine to EDNO or EDRF either through enzymatic activation or increasing gene expression (i.e. increased protein levels of c-NOS). Of course, either or both of these mechanisms may be acting simultaneously.
- 19 It is an object of this invention to provide a method of preventing, treating, arresting, or ameliorating disease conditions which are benefited by the bio-transformation of a substrate into endogenous nitric oxide or "native" nitric oxide.
- 20 It is another object of this invention to provide a method of preventing, treating, arresting, or ameliorating disease conditions which are benefited by the bio-transformation of L-arginine into "native" nitric oxide through enzyme activation of NOS.
- 21 It is another object of this invention to ameliorate or avoid tachycardia and prevent or treat ischemia.
- 22 It is another object of this invention to achieve a beneficial effect when treating disease conditions by increasing or maximizing the production of "native" nitric oxide, and reducing clinical endpoints to include mortality.
- 23 It is another object of this invention to prevent reperfusion injury in subjects who have had abrupt restoration of blood flow.
- 24 It is a further object of this invention to provide a mixture of inhibitors of Hmg-CoA reductase and biological equivalents of L-arginine for the treatment of hypertension, hypertensive heart disease, coronary heart disease, including arteriosclerosis, angina, myocardial infarction, coronary thrombosis, restenosis post angioplasty, and sudden death, as well as a wide range of cardiovascular disease (heart failure, stroke, and peripheral vascular diseases), and renovascular ischemia/hypertension.
- 25 These and other objects of this invention are provided by one or more of the embodiments provided below.
- 26 In one embodiment of the invention, therapeutically effective amounts of a precursor of EDNO and an agonist of NOS are combined prior to administration to a patient. In another embodiment of the invention, therapeutically effective amounts of a precursor of EDNO and an agonist of NOS are combined prior to administered separately and mixed "in vivo".

- 27 In another embodiment of the invention, therapeutically effective amounts of L-arginine and inhibitors of Hmg-CoA reductase are mixed at a physiologically acceptable pH and administered to a patient.
- 28 In another embodiment of the invention a method for treating hypertension in a subject by vasodilation or vasorelaxation comprises: selecting a hypertensive subject; administering L-arginine and Hmg-CoA reductase inhibitors to the subject; obtaining periodic blood pressure measurements of the subject; and continuing administration of L-arginine and Hmg-CoA reductase inhibitors until a desirable blood pressure or therapeutic effect is detected in the subject. A desirable blood pressure in a hypertensive subject should ultimately be within the following ranges: systolic preferably in the range of 95-180 mmHg, more preferably in the range of 105-165 mmHg, and even more preferably in the range of 120 to 140 mmHg; and diastolic preferably in the range of 55-115 mmHg, more preferably in the range of 65-100 mmHg, and even more preferably in the range of 70 to 90 mmHg, and most preferably 75-85 mmHg. Under no circumstances should the systolic be permitted to go below 95 mmHg.
- 29 Another embodiment of the present invention is a method for preventing or treating cardiovascular disease in a non-hypertensive subject by vasodilation or vasorelaxation comprising: selecting a subject; administering to said subject a formulation comprising a mixture of an inhibitor of Hmg-CoA reductase and an endothelium dependent source of nitric oxide (i.e., L-arginine); obtaining periodic measurements of vasorelaxation on the subject and; continuing administration of the formulation until a desirable state of vasorelaxation or desirable therapeutic effect is detected on the subject. A desirable state-of vasorelaxation is for example a lowering of the systolic by about 20 mmHg and a lowering of the diastolic by about 10 mmHg. Under no circumstances should the systolic be lowered less than 95 mmHg.
- 30 Yet another embodiment is a method for stimulating cNOS in a subject which comprises: selecting a subject; administering to said subject a formulation comprising a mixture of L-arginine and inhibitors of Hmg-CoA reductase, so as to maximize "native" NO production and reduce endpoints to include mortality.

DRAWING DESCRIPTION:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of the proposed NOS activation pathway.

FIG. 2 is a bar graph illustrating the stimulation of NOS with pravastatin.

DETAILED DESCRIPTION:

1 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

- 2 From the data presented herein it appears that inhibitors of Hmg-CoA reductase may have dual applicability in the treatment of hypertension and cardiovascular diseases such that they act as both an inhibitor of the intrinsic biosynthesis of cholesterol and a stimulator or agonist of nitric oxide synthase. The fact that Hmg-CoA reductase may be agonist or stimulant of nitric oxide synthase has remarkable implications. Mixing inhibitors of Hmg-CoA reductase "in vitro" or "in vivo" with L-arginine has been found to have an unforeseen beneficial effect that is most likely due to excess L-arginine providing additional substrate for the nitric oxide synthase and the NOS being catalyzed to enzymatically increase the bio-transformation of L-arginine into nitric oxide.
- 3 Stimulation of NOS in the presence of excess L-arginine or other substrate precursor of native NO (EDRF or EDNO) may be used to prevent, treat, arrest, or ameliorate any disease or condition which is positively affected by NO production.

Such conditions include hypertensive cardiocerebrorenovascular diseases and their symptoms as well as non-hypertensive cardiocerebrorenovascular diseases. The mixture is particularly useful for subjects in need of native NO production. Application of such a mixture is beneficial for: (1) Chronic stable angina; (2) Unstable angina; (3) Acute myocardial infarction; (4) Hibernating myocardium; (5) Stunned myocardium; (6) Limitation of ventricular remodeling in post myocardial infarction and subsequent risk of congestive heart failure; (7) Prophylaxis of recurrent myocardial infarction; (8) Prevention of sudden death following myocardial infarction; (9) Vasospastic angina; (10) Congestive heart failure-systolic-seen in association with 1-6 above; (11) Congestive heart failure-diastolic-seen in association with 1-10 above and 12-15 below; (12) Microvascular angina seen in association with 1-11 above and 15 and 16 below; (13) Silent ischemia seen in association with 1-12 above and 15 and 16 below; (14) Reduction of ventricular ectopic activity seen in association with 1-13 above and 15 below; (15) Any or all of the above 1-14 states of ischemic myocardium associated with hypertensive heart disease and impaired coronary vasodilator reserve; (16) control of blood pressure in the treatment of hypertensive crisis, perioperative hypertension, uncomplicated essential hypertension and secondary hypertension; (17) Regression of left ventricular hypertrophy seen in association with 15 and 16 above; (18) Prevention and or regression of epicardial coronary arteriosclerosis seen in 1-17 above; (19) Prevention of restenosis post angioplasty; (20) Prevention and/or amelioration of free radical mediated reperfusion injury in association with 1-19 above; (21) Use of the combination in the prevention of myocardial injury during cardioplegic arrest during coronary bypass or other open heart surgery i.e. use of the combination as a cardioplegic solution; (22) Post transplant cardiomyopathy; (23) Renovascular ischemia; (24) Cerebrovascular ischemia (TIA) and stroke); and (25) Pulmonary hypertension.

- 4 Vascular smooth muscle cells are located mainly in veins, arteries, and coronary arteries. The following discussion focuses on smooth muscle and myocyte relaxation stimulated by vasodilators. As discussed above the nitric oxide synthase in the cells is normally cNOS, the constitutive form of nitric oxide synthase, and the generator cells are endothelial cells and the target cells are vascular smooth muscle cells. FIG. 1 is a schematic illustration and is not intended to imply any cellular relationship or geography of the various sites of action, but rather meant to illustrate their functional relationship.
- 5 The principle combination to be employed will be a mixture that involves therapeutic concentrations of L-arginine and a Hmg-CoA reductase inhibitor in water. Any pharmaceutical grade L-arginine will be sufficient and should be diluted preferably to 2.5-60% w/v (g/ml), more preferably to 5-45% w/v (g/ml), even more preferably between 7.5-30% w/v (g/ml), even more preferably to 10-15% w/v (g/ml), and most preferably 10% w/v (g/ml) L-arginine. The typical doses anticipated will be 30 grams of L-arginine in sterile water (Total Volume 300 cc). L-arginine is anticipated eventually to be approximately 10:1 to about 25:1 of the hydrochloride salt to L-arginine as a base, and even more preferably 15:1 to about 20:1 hydrochloride salt to base, and most preferably 15:1 hydrochloride salt to base. In this example 28 to 29 grams will be the hydrochloride salt and 1 to 2 grams of L-arginine will be base.
- 6 L-arginine may be used in conjunction with virtually any of the family of those substances known as Hmg-CoA reductase inhibitors. Those particular Hmg-CoA reductase inhibitors most preferred for use in conjunction with the present formulation as selected from the group consisting of: simvastatin, lovastatin, pravastatin, compactin, fluvastatin, dalvastatin, HR-780, GR-95030, CI-981, BMY 22089, and BMY 22566. U.S. Pat. No. 5,316,765 cites a number of these Hmg-CoA reductase inhibitors and is hereby incorporated by reference in its entirety. In particularly preferred embodiments of the present invention, the Hmg-CoA reductase inhibitor utilized is pravastatin or lovastatin. In an even more particularly preferred embodiments, the administration of the present invention includes the Hmg-CoA reductase inhibitor pravastatin.
- 7 As part of a "mixture", the Hmg-CoA reductase inhibitor is included together with L-arginine and clinically effective weight ratios of between 1:2 to 1:150. Even more particularly, the ratio of the Hmg-CoA reductase Larginine in the formulation

is between 1:5 to 1:100. The most preferred embodiment of the "mixture" the ratio of Hmg-CoA reductase inhibitor, most particularly pravastatin, to L-arginine is 1:50. The range of ratios of an Hmg-CoA reductase inhibitor to L-arginine may be employed with virtually any Hmg-CoA reductase inhibitor.

- 8 Where the particular Hmg-CoA reductase inhibitor is pravastatin, the ratio of pravastatin to L-arginine is preferably within the range 1:2 to 1:50, Wt/Wt. For example, pravastatin/L-arginine at a ratio of 1:2 would include 40 mg/day pravastatin with 80 mg/day L-arginine. Where the ratio of pravastatin/L-arginine is at a ratio of 1:20, for example, 20 mg/day pravastatin would be administered with 400 mg/day L-arginine. Weight ratio of ingredients described herein in regard to the Hmg-CoA reductase inhibitors, lovastatin and pravastatin are applicable for any Hmg-CoA reductase inhibitor. The amounts above have been found to be effective, however, each route of administration (i.e. IV, oral, transdermal, etc.) will vary in their requirements.
- 9 Even more particularly, the presently disclosed "mixtures" may be described in terms of their relative concentrations (grams) administered as part of a continuous daily and/or monthly regimen. In one particular embodiment, the formulation is administered so as to provide the patient with between 20-40 milligrams per day of the Hmg-CoA reductase inhibitor (i.e., pravastatin) together with a daily dose of L-arginine of between 100 to 200 mg per day. Most preferably, the Hmg-CoA reductase inhibitor, such as lovastatin, is administered at a daily dose of about 20 mg per day together with a dose of about 200 mg per day L-arginine. This particular embodiment of the claimed formulation should maintain within the patient efficient levels of the formulation.
- 10 By way of example only, Table 1 presents a listing of several inhibitors of Hmg-CoA reductase. These substances vary in their potency and their abilities to inhibit Hmg-CoA.

TABLE 1

Simvastatin

Lovastatin

Pravastatin

Compactin (a.k.a., mevastatin)

Fluvastatin

Dalvastatin

GR-95030

HR-780

SQ 33,600

BMV 22089

BMV 22566

CI 981

- 11 The Hmg-CoA reductase inhibitors of the present invention are also characterized by an ability to stimulate receptor-mediated clearance of hepatic low-density lipoproteins (LDL), as an anti-hypercholesterolemic, and as a competitive inhibitor of Hmg-CoA reductase.

- 12 The Hmg-CoA reductase inhibitor employed may be lovastatin, simvastatin, pravastatin, XU-62-320 (Sodium 3.5-dihydroxy-7 [3-(4-fluorophenyl)-1(methylethyl)-IH-Indole-2yl]-hept-6-enoate), mevastatin (a.k.a., compactin), BNY 22089, CI-981, SQ 33,600, BMY 22089, CI 981, HR 780, SQ 33,600 or any other member of the class of compounds that inhibit Hmg-CoA reductase. The preparation of lovastatin, simvastatin, and pravastatin have been described in the patent literature. The preparation of XU-62-320 (fluvastatin) is described in WIPO Patent W084/02131. BMY 22089(13), CI 981(14), HR 780(15), and SQ 33,600(16) are also described in the literature cited, and are specifically incorporated herein by reference for the purpose of even more fully describing the chemical structure and synthesis of these Hmg-CoA reductase inhibitors. These methods of preparation are hereby incorporated by reference in their entirety.
- 13 Also within the scope of those Hmg-CoA reductase inhibitors of the present invention are included the bio-active metabolites of those compounds listed in Table 1, such as pravastatin sodium (the bio-active metabolite of mevastatin).
- 14 Any one or several of those Hmg-CoA reductase inhibitor compounds listed in Table 1 pravastatin may be mixed with L-arginine or substrate precursor to endogenous nitric oxide to provide a therapeutically effective treatment for a patient.
- 15 Until now there was no link between the bio-transformation of L-arginine into "native" nitric oxide and anti-hypocholesterolemic Hmg-CoA reductase inhibitors. However, it is now believed that Hmg-CoA reductase inhibitors has a stimulating effect on cNOS. The mechanism is not well understood but it appears the mixture of inhibitors of Hmg-CoA reductase and L-arginine may have a heretofore unexpected synergistic effect on cNOS stimulation. The stimulation of cNOS may be a result of cNOS having a unique receptor site for Hmg reductase inhibitors or inhibitors of Hmg-CoA reductase initiating a cascade of events which stimulate NO. Administering the two also provides adequate substrate for cNOS processing of L-arginine since the L-arginine is added in excess while at the same time stimulation the enzymatic activity of NOS. Whether it is a synergistic effect or additive effect, what is clear is that "mixing" a precursor substrate of "native" nitric oxide with a Hmg-CoA reductase inhibitor results in a heretofore unexpected increase in NO production. This unexpected affect is demonstrated in the example below.
- 16 EXAMPLE
- 17 The direct effects of acteylcholine and pravastatin on NO production in bovine aortic endothelial cells (BAEC) was determined using a highly sensitive photometric assay for conversion of oxyhemoglobin to methemoglobin. NO oxidize; oxyhemoglobin (HbO.sub.2) to methemoglobin (metHb) in the following reaction HbO.sub.2 +NO-metHb+NO.sub.3. The amount of NO produced by endothelial cells was quantified by measuring the change in absorbance as HbO.sub.2 oxidizes to metHb. Oxyhemoglobin has a absorbance peak at 415 nm, while metHb has a 406 nm absorbance peak. By subtracting the absorbance of metHb from HbO.sub.2, the concentration of NO can be assessed. The general method was patterned after that of Feelisch et al., (Biochem. and Biophy. Res. Comm. 1991; 180, Nc I:286-293).
- 18 For this assay, endothelial cells were isolated from bovine aortas. BAECs were grown to confluency in 150 mm plates (Corning) using Medium 199 supplemented with penicillin G (100 mL.sup.-1), streptomycin (100 mg mL.sup.-1), glutamine (100 mg mL.sup.-1), thymidine (100 mg mL.sup.-1), and 10% fetal calf serum (Gibco). Upon confluency, cells will be washed twice with a 1% phosphate buffered saline/EDTA solution. Tripsin/EDTA was added and the cells were kept at 37.degree. C. until the cells become rounded thus signaling detachment from the plate. An equal amount of trypsin inhibitor was added to inhibit any further trypsin activity that might damage the cells. The cells were pelleted by spinning at 150-200 g for 5 min. Cells were resuspended in culture medium and approximately 10.sup.7 of these cells were used to inoculate 0.5 g of micro-carrier beads (Cytodex #3). Cells, beads and medium was transferred to a spinner flask (Wheaton) where the culture sat undisturbed at 37.degree. C. with 95% O.sub.2 and 5% CO.sub.2 for 29 min then spun (20 rpm) in this same environment for 1 min. This sitting cycle allowed for cell adherence to the beads while the spinning created an even distribution of cells

and beads. After 4 hrs of this attachment phase, the spinner flask was left on the stirrer at slow speed for 2-3 days for uniform cellular coating of beads.

- 19 Beads/cells were rinsed twice and then suspended in a Hepes-buffered Krebs-Ringer solution containing all necessary co-factors. To prevent a reaction between NO and superoxide (O₂sup.⁻), superoxide dismutase (200 U/ml) was added to the buffer. Catalase (100 U/ml) will be added to decompose hydrogen peroxidase, keeping the hemoglobin active. Two ml of EC/beads were placed into a water-jacketed chromatography column (Pharmacia) and superfused at 2 ml/min with Hepes-buffered Krebs-Ringers solution containing 3 uM oxyhemoglobin. The perfusate was then directed into a flow-through cuvette in a dual wavelength spectrophotometer and absorbance was measured to determine the basal and stimulated NO release. A parallel column circuit was filled with only beads (no cells) to determine basal and spontaneous release of NO in this system without cells. Vehicle (buffer w/o agent) did not cause a change in absorbance when infused into the cell-bead column.
- 20 Experimental stimulation were carried out by 3 min infusion periods of acetylcholine (ACH) or pravastatin (PRA) added to buffer perfusion using a micro syringe pump at a rate of 45 ul/min to yield a final concentration of 10.sup.-6 and 10.sup.-5 M for ACH and 10.sup.-6 and 10.sup.-5 M for PRA in the buffer. The effects of buffer containing L-Name (10.sup.-3 M) in blocking the actions of these drug agents and then a buffer without L-NAME but with excess L-arginine (10.sup.-3 M) in reversing any L-NAME effect was examined. Each drug agent concentration was given twice for each of the three buffer systems; a period of 10 min was allowed between infusion of agents. Our data demonstrate that this cell perfusion and monitoring system remains stable for at least 4-6 hours. At the end of each experiment, cell viability was checked using trypan blue exclusion.
- 21 For analysis, we determined the area under the curve for the change in absorbance response/unit time (min) caused by each agent above baseline levels and calculated methHb production using an extinction coefficient of 39 mM.sup.1. During the 3 min infusion of agents, absorbance increases rapidly. Changes in absorbance to these agents usually persist from 2-8 mins depending on the size of the response before returning to baseline levels. We assume a one to one correspondence for NO and methHb production, the known stoichiometric balance for this reaction. We also determined changes in basal NO production during perfusion with each of the buffer systems. Basal NO values were subtracted from any drug-induced responses to determine NO production which results from the drug's actions. Table 2 recites the results of these experiments.

TABLE 2

Basic Buffer 10.sup.-3 M L-NAME 10.sup.-3 M L-arginine

(absolute production of NO in nmole* min)

10.sup.-6 M Ach	197.60	72.20	330.60
10.sup.-5 M Ach	619.40	288.80	756.20
10.sup.-6 M Prav.	163.40	45.60	201.40
10.sup.-5 M Prav.	513.00	209.00	752.40

- 22 FIG. 2 is a bar graph of the data generated which illustrates the effects of acetylcholine and pravastatin (10.sup.-6 and 10.sup.-5 M) administered for 3 min periods into the cell/bead perfusion system on NO production with: 1) 10.sup.-5 M L-arginine in control (basic) buffer, 2) 10.sup.-3 M of L-NAME in buffer, and 3) 10.sup.-3 M of L-arginine in buffer. Responses are transient elevations in NO production above basal levels. Data for responses in L-NAME and L-arginine

augmented buffer are presented as percent of response in control buffer (100%); numbers in basic buffer bars indicate absolute production of NO in nmole *min. The remaining two bars denote differences between responses in L-NAME buffer vs both basic and L-arginine added buffers.

- 23 The effects of pravastatin on activity of endothelial cells in producing NO were compared with those of acetylcholine, which is known to specifically stimulate NO production by NOS activity. Adding acetylcholine to the buffer superfusion bovine aortic endothelial cells (BAECs) grown on beads increased their production of NO as measured by oxidation of oxyhemoglobin to methemoglobin (FIG. 2) Acetylcholine produced a transient, concentration-related increase in NO above baseline levels. In basic buffer containing 5.times.10.sup.-5 M L-arginine, and there was approximately a two fold increase in NO production between 10.sup.-5 M L-arginine, there was approximately a two fold increase in NO production between 10.sup.-5 and 10.sup.-6 M acetylcholine. Subsequent treatment of these cells with buffer containing L-NAME, 10.sup.-3 M markedly reduced acetylcholine-induced production of NO by 80%. When this L-NAME buffer was replaced with another containing increased L-arginine (10.sup.-3 M), acetylcholine-elicited production of NO returned to control levels.
- 24 Pravastatin also caused a concentration-related increase in NO production above baseline levels. There was a larger increment in response to the 10.sup.-5 M concentrations of pravastatin (.about.3 X) compared with that of acetylcholine. Superfusion of the cell suspension with L-NAME (10.sup.-3 M), also blunted NO production in response to pravastatin. This suggests that NO production is due at least in part to NOS activity. Subsequent perfusion of the cells with a buffer containing L-arginine 10.sup.-3 M resulted in a return in NO production to a level above the amount induced by the Pravastatin in control (basis) buffer. This restoration of response to Pravastatin after L-arginine addition was greater than that observed for acetylcholine. Administration of Pravastatin or acetylcholine into a perfusion system containing only beads without cells did not induce metHb/NO production.
- 25 As can be seen from Table 2 and FIG. 2, pravastatin appears to stimulate cNOS in much the same way as other NOS agonist described in U.S. Pat. No. 5,543,430 independent of its inhibitory effect on cholesterol biosynthesis.
- 26 Although the preferred methods have been described in detail, it should be understood that various changes, substitutions, and alterations can be made in the present invention as defined by the claims appended hereto. For example, other cNOS agonist may be identified. An example of a contemplated formulation is a mixture of estrogen and L-arginine since preliminary data indicates that estrogen may be functioning as a NOS agonist. The present invention is defined by the claims attached hereto.

CLAIMS:

What is claimed is:

1. A method for treating a subject who would benefit from increased Nitric Oxide production in a tissue comprising: administering to the subject in need of such treatment, irrespective of the subject's cholesterol level, a Hmg-CoA reductase inhibitor in an amount effective to increase Nitric Oxide production in said tissue of the subject.
2. The method of claim 1 wherein the subject is nonhyperlipidemic.
3. The method of claim 2 wherein said amount is sufficient to increase Nitric Oxide production above normal baseline levels.
4. The method of claim 2 wherein the subject has a cytokine-induced condition comprising an abnormally low level of nitric oxide synthase activity.
5. The method of claim 2, wherein the subject has an abnormally elevated risk of pulmonary hypertension.

6. The method of claim 2, wherein the subject has pulmonary hypertension.
7. The method of claim 1 wherein the subject has a condition comprising an abnormally low level of endothelial cell Nitric Oxide Synthase activity.
8. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of simvastatin, lovastatin, pravastatin, compactin, fluvastatin, and dalvastatin.
9. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is simvastatin.
10. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is lovastatin.
11. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is pravastatin.
12. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is fluvastatin.
13. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is dalvastatin.
14. The method of claim 1 wherein the Hmg-CoA reductase inhibitor is compactin.



Generate Collection

L4: Entry 3 of 6

File: USPT

Jun 16, 1998

DOCUMENT-IDENTIFIER: US 5766909 A

TITLE: DNA encoding inducible nitric oxide synthase

Detailed Description Text (2):

The present invention relates to unique cDNA encoding inducible nitric oxide synthase (iNOS) which is isolated and purified from macrophages, macrophage like cells and macrophage cell lines. Isolated and purified inducible NOS, as used herein, refers to an enzyme which in combination with cofactor(s) results in the generation of nitric oxide from L-arginine. The cofactors include, but are not limited to, NADPH and FMN and tetrahydrobiopterin. Other acceptable cofactors have been described by Stuehr, et al., Biochem. Biophys. Res. Comm. 168: 228-565 (1990). Enzyme activity is evaluated according to an assay described by Stuehr et al., Proc. Natl. Acad. Sci. USA 88: 7773-7777 (1991). Enzymatically active refers to a protein which can catalyze the formation of nitric oxide and is capable of being induced in macrophage like cells and other cell types. Macrophage is defined herein as a cell of the mononuclear phagocytic system and includes both fixed and circulating phagocytic cells. It is also within the scope of this invention that iNOS cDNA or gene may be isolated from other phagocytic cells following induction with interferon gamma (IFN.gamma.) and bacterial lipopolysaccharide (LPS). Although the iNOS cDNA of this invention is described as being isolated from mouse cells, the same or substantially similar iNOS may be isolated from other mammalian cells, including human cells. Indeed, recent experiments have shown that a unique human brain cDNA segment (PCR product) which encodes a partial sequence of human cNOS has a deduced amino acid sequence that is very similar to the rat deduced sequence as shown in Bredt et al., Nature 351: 714-718 (1991). Of the approximately 220 human cNOS amino acids characterized there were only three residues which were different. This indicates that human iNOS will have an amino acid sequence substantially similar to mouse iNOS even though the nucleotide sequences may not have equivalent similarities.